A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Trial Profile

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Osimertinib (Primary) ; Savolitinib (Primary) ; Durvalumab; Selumetinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms TATTON
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Oct 2017 Results presented in an AstraZeneca media release.
    • 16 Oct 2017 According to an AstraZeneca media release, results from this trial were presented at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer (WCLC).
    • 16 Oct 2017 Results presented in an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top